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Background
Recent research highlight that newly synthesized HIV-1
capsid protein is required to induce dendritic cell activa-
tion through a pathway involving interaction with pepti-
dyl-prolyl cis-trans isomerase cyclophilin A (CYPA),which
subsequently induce an antiviral type I interferon response
and activation of T cells.
Previous studies also revealed HIV Gag-CYPA interac-
tion inhibited recognition by host restriction factors. In
another perspective, the inhibition effect might be benefit
for HIV Gag immunogenicity.
Consequently, we assume CYPA might be a potential
genetic adjuvant co-inoculation with HIV-1 Gag DNA
vaccine, which not only circumvent the restriction of host
factors, but also activate dendritic cell and enhance adap-
tive immune response.
Methods
In this study, 6-8-week-old female BALB/C mice were
administrated thrice intramuscularly with pDRVI4.0-Gag
HIV-1 DNA vaccine co-formulated with pDRVI4.0-CYPA
plasmid at two weeks interval. IFN-g ELISPOT, Gag-speci-
fic ELISA, IgG isotype ELISA detected cellular and
humoral immunological response.
Results
The regimen of HIV-1 Gag DNA premixed with CYPA
DNA induced robust immune responses in mouse model.
IFN-g ELISPOT result demonstrated Gag DNA alone only
generated 180 ± 63(mean ± SD) SFCs/million. However,
Gag DNA combined with CYPA DNA strategy produced
353 ± 80(mean ± SD) SFCs/million. In humoral immune
response, Gag DNA co-inoculation with CYPA DNA
showed high level antibody titer (GMT=22800),whereas
Gag DNA alone induced slight antibody response
(GMT=8000). IgG isotype results confirmed that co-vacci-
nation with CYPA DNA induced Th1-bias immune
response, however, Gag DNA alone activated Th1/Th2
response in balance.
Conclusion
This is the first report demonstrating that mixture of
CYPA DNA and HIV-1 gag DNA vaccine could induce
robust cellular and humoral immune response in the
mouse model. Ongoing studies are focusing on construc-
tion of dual expression cassette DNA vaccine, which
including both Gag and CYPA gene. Further research will
also construct others HIV DNA vaccine involving human
or non-human primates CYPA.
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